サンプル依頼リスト カート
  • English
  • Korean
表紙：バイオプロセス技術の世界市場-2023年～2030年
市場調査レポート
商品コード
1374837

バイオプロセス技術の世界市場-2023年～2030年

Global Bioprocess Technology Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 185 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
バイオプロセス技術の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 185 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

バイオプロセス技術とは、生きた細胞やその成分が関与する生物学的プロセスを産業応用し、基質を所望の形に変換する技術です。従来の化学プロセスに対するバイオプロセスの主な利点は、穏やかな反応条件を必要とすること、より特異的で効率的であること、再生可能な製品別（バイオマス）を生産することです。組換えDNA技術の開発は、バイオプロセスの可能性を拡大し、拡張しました。

バイオプロセスまたはバイオテクノロジーは、バイオリアクター内で酵素、微生物、植物細胞、動物細胞などの生体触媒の助けを借りて、医薬品、食品、香料、燃料、化学物質を生産する際に使用されます。また、植物、動物、酵母、細菌、真菌などの微生物を操作するための遺伝子工学も含まれます。

市場力学：市場促進要因と市場抑制要因

バイオテクノロジー企業や製薬企業別研究開発投資の増加

バイオテクノロジー企業や製薬企業による研究開発投資の増加は、予測期間中に市場が成長する主な要因の1つです。製薬企業のバイオテクノロジーへの移行が開発の可能性を生み出したため、バイオ医薬品業界は医療・製薬業界全体に根を張っています。

例えば、2022年7月にBiotechnology Reportに掲載された記事によると、3Dバイオプリンティング、バイオセンサー、遺伝子編集のようなバイオ医薬品・製薬分野の成長する技術開発、最先端の人工知能や仮想現実・拡張現実の取り込みは、バイオプロセスによる生産の増加とスピードアップによって成長機会を開くと期待されています。

さらに2022年10月、Oculis SAとEuropean Biotech Acquisition Corp.は、最終的な事業統合契約を締結したと報告しました。この契約は、オクリス社の差別化された眼科用パイプラインの開発を加速させるものです。この製品は、糖尿病性黄斑浮腫（DME）、ドライアイ（DED）、緑内障などの神経網膜の適応症など、医療ニーズの高い分野に対応するもので、患者数の増加に影響を与えています。

さらに、バイオプロセス技術の研究開発資金の増加が、世界のバイオプロセス市場の成長を促進すると推定されます。さらに、バイオプロセスにおける継続的な技術進歩や、バイオ燃料生産に関する各国政府からの支援の増加が、バイオプロセス技術市場の成長をさらに促進すると予想されます。

市場力学：市場抑制要因

厳しい規制は、予測期間中の市場成長を妨げる要因の一つです。バイオプロセス技術分野の市場関係者は、成長ペースで前進することが難しいと感じています。世界中の多くの政府がすでに行動を起こしており、中には市場機器の高コストを背景に厳しい規制と政策を選択する政府もあり、予測期間中の市場拡大を妨げています。また、技術コストの高さや熟練した専門家の不足も、予測期間中の市場成長を妨げる要因となっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • バイオテクノロジー企業や製薬企業による研究開発投資の増加
      • 技術の進歩
    • 抑制要因
      • 規制上の課題
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 製品タイプ別

  • バイオリアクター
  • 装置
  • バイオプロセス分析装置
  • 浸透圧計
  • インキュベーター
  • その他

第8章 消耗品・アクセサリー別

  • 培地
  • 試薬
  • その他

第9章 用途別

  • 組み換えタンパク質
  • モノクローナル抗体
  • 抗生物質
  • その他

第10章 エンドユーザー別

  • バイオ製薬企業
  • CMO（医薬品製造受託機関）
  • 学術研究機関
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Thermo Fisher Scientific Inc
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Sartorius
  • Roche
  • Repligen
  • Merck
  • SolidaBiotech
  • Univercellstech
  • Advanced Instruments
  • ELITechGroup Inc
  • Cytiva（LIST NOT EXHAUSTIVE）

第14章 付録

目次
Product Code: BT7376

Overview

Bioprocess technology is the industrial application of biological processes involving living cells or their components to effect the desired transformation of substrates. The major advantages of bioprocesses over traditional chemical processes are that they require mild reaction conditions, are more specific and efficient, and produce renewable by-products (biomass). The development of recombinant DNA technology has expanded and extended the potential of bioprocesses.

Bioprocessing or biotechnology is used in the production of pharmaceuticals, foods, flavours, fuels and chemicals with the aid of a biocatalyst such as an enzyme, microorganisms, plant cell, or animal cell in a bioreactor. It also involves genetic engineering for the manipulation of plants, animals, and microorganisms such as yeasts, bacteria and fungi.

Market Dynamics: Drivers and Restraints

Rise in investments in research and development by biotechnology and pharmaceutical companies

The rise in investments in research and development by biotechnology and pharmaceutical companies is one of the key factors that helps the market to grow during the forecast period. Because of the transition of pharmaceutical firms towards biotechnology, which has created development potential, the biopharmaceutical industry has strengthened its roots across the medical and pharmaceutical industries.

For instance, an article published in the Biotechnology Report in July 2022 stated that growing technological developments in biopharmaceutical and pharmaceutical sectors like 3D bioprinting, biosensors, and gene editing, as well as the incorporation of cutting-edge artificial intelligence and virtual and augmented reality, are expected to open growth opportunities by increasing and speeding the production through bioprocessing.

Moreover, in October 2022, Oculis SA and European Biotech Acquisition Corp. reported they had entered into a definitive business combination agreement. This agreement is to accelerate the development of Oculis' differentiated ophthalmology pipeline. This product addresses areas of significant medical need, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications, such as glaucoma, affecting growing patient populations.

Furthermore, an increase in the funding for research and development of bioprocessing technology is estimated to propel the growth of the global bioprocess market. Continuous technological advancements in the bioprocess Moreover, increasing support from the governments of various countries in terms of biofuel production is further expected to drive the growth of the bioprocess technology market.

Market Dynamics: Restraint

Strict regulations are one of the factors that hamper the market growth during the forecast period. The market players in the bioprocess technology sector find it difficult to advance at the growth pace. Many governments around the world have already taken action, and some of them are choosing to impose severe regulation policies backed by the high cost of the market instruments that are preventing the market from expanding during the projected period. Also, the high cost of technology and lack of skilled professionals are the factors that hamper the market growth during the forecast period.

Segment Analysis

The global bioprocess technology is segmented based on product type, consumables and accessories, application, end-user and region.

The bioreactors from the product type segment accounted for approximately 39.2% of the market share

The bioreactors from the product type segment accounted for approximately 39.2 % and it is expected to be dominated during the forecast period. A bioreactor is an indispensable part of any bioprocess irrespective of whether the process degrades pollutants or produces substances such as foods, feeds, chemicals and pharmaceuticals, and tissues and organs for use in biomedicine.

For instance, in August 2023 Sartorius and Repligen launched an integrated bioreactor system that incorporates Repligen Xcell ATF upstream intensification technology into Sartorius' Biostat STR bioreactor. The goal is to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers, according to both companies.

Moreover, in March 2022 Argentinian biotechnology firm Stamm Biotech has reportedly closed a $17 million Series A funding round which will help the company accelerate the development of its next-generation 3D printed bioreactor. The firm is developing its microfluidics-based bioreactor using its proprietary self-developed Brick Printing Technology which powers its Sclereid 3D printer. According to Stamm, the 3D printer's capabilities could extend to building the installed capacity of bioreactors worldwide for biopharma in just one year.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the escalating demand for quality biologics and the rising investments in R&D activities by the major players. Moreover, the high prevalence of chronic diseases that mostly use biopharmaceuticals for treatments and the established healthcare infrastructure in the region has significantly contributed to the industry growth.

For instance August 2022 Beckman Coulter Life Sciences announced a partnership with Flownamics to create an automated, online solution for bioprocess culture monitoring and control. This automated integration removes error-prone manual steps while enabling load-and-go sample runs for up to eight bioreactors, GMP compliance with electronic data management, and continuous control of viable cell density, including remote workflows.

COVID-19 Impact Analysis

The COVID-19 pandemic has created unprecedented stress on supply chains in nearly every global manufacturing segment. Bioprocessing and healthcare have been hit especially hard as suppliers struggle to find materials to meet the demand for COVID-19 vaccines and therapeutics. On top of ongoing non-COVID biologics projects being manufactured, this has created serious supply chain stress.

Market Segmentation

By Product Type

  • Bioreactors
  • Instruments
  • Bioprocess Analyzers
  • Osmometers
  • Incubators
  • Others

By Consumables and Accessories

  • Culture Media
  • Reagents
  • Others

By Application

  • Recombinant Proteins
  • Monoclonal Antibodies
  • Antibiotics
  • Others

By End-User

  • Biopharmaceutical Companies
  • Contract Manufacturing Organizations
  • Academic Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in bioprocess technology market include: Thermo Fisher Scientific Inc., Sartorius, Roche, Repligen, Merck, SolidaBiotech, Univercellstech, Advanced Instruments, ELITechGroup Inc, Cytiva and among others.

Key Developments

  • In July 2023 Molecular Devices, LLC., a leading high-performance life science solutions provider, continues industrializing biology with its organoid line expansion services to support next-generation drug discovery. The offering leverages proprietary bioreactor and bioprocess technology to scale up the production of standardized, assay-ready organoids originating from customer-supplied organoid lines or patient-derived xenografts (PDX).
  • In October 2022 PharmNXT Biotech unveils its first integrated manufacturing unit for single-use bioprocessing systems. In line with 'Make in India', the Government's flagship program, Mumbai-based PharmNXT Biotech launched its first integrated manufacturing unit in Pune to provide single-use bioprocessing solutions. The facility has been launched to address the challenges of biologics manufacturing in the country.
  • In June 2022 Merck, a leading science and technology company, announced that it has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0.

Why Purchase the Report?

  • To visualize the global bioprocess technology market segmentation-based product type, consumables and accessories, application, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous bioprocess technology market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global bioprocess technology market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Consumables and Accessories
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Rise in investments in research and development by biotechnology and pharmaceutical companies
      • 4.1.1.2. Rise in the technology advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Regulatory Challenges
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Bioreactors*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Instruments
  • 7.4. Bioprocess Analyzers
  • 7.5. Osmometers
  • 7.6. Incubators
  • 7.7. Others

8. By Consumables and Accessories

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Consumables and Accessories
    • 8.1.2. Market Attractiveness Index, By Consumables and Accessories
  • 8.2. Culture Media*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Reagents
  • 8.4. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Recombinant Proteins *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Monoclonal Antibodies
  • 9.4. Antibiotics
  • 9.5. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Biopharmaceutical Companies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Contract Manufacturing Organizations
  • 10.4. Academic Research Institutes
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Consumables and Accessories
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Consumables and Accessories
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Consumables and Accessories
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Consumables and Accessories
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Consumables and Accessories
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Thermo Fisher Scientific Inc
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Sartorius
  • 13.3. Roche
  • 13.4. Repligen
  • 13.5. Merck
  • 13.6. SolidaBiotech
  • 13.7. Univercellstech
  • 13.8. Advanced Instruments
  • 13.9. ELITechGroup Inc
  • 13.10. Cytiva (LIST NOT EXHAUSTIVE)

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us